BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37349334)

  • 1. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
    Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
    Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
    Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
    Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
    [No Abstract]   [Full Text] [Related]  

  • 3. Arsenic: a new place?
    Vincent PC
    Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
    [No Abstract]   [Full Text] [Related]  

  • 4. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
    Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
    Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
    Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
    [No Abstract]   [Full Text] [Related]  

  • 6. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 7. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
    Au WY; Lang BH; Fong BM; Mao KJ; Tam S
    Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
    [No Abstract]   [Full Text] [Related]  

  • 8. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

  • 9. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
    Korístek Z; Zák P
    Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
    Firkin F
    Leuk Lymphoma; 2014 May; 55(5):977-8. PubMed ID: 24144311
    [No Abstract]   [Full Text] [Related]  

  • 11. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
    Komatsu N
    Int J Hematol; 2014 Jul; 100(1):16-7. PubMed ID: 24912657
    [No Abstract]   [Full Text] [Related]  

  • 12. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Barbey JT; Soignet S
    Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
    Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
    Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
    Roberts TF; Sprague K; Schenkein D; Miller KB; Relias V
    Blood; 2000 Dec; 96(12):4000-1. PubMed ID: 11186272
    [No Abstract]   [Full Text] [Related]  

  • 17. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Galm O; Fabry U; Osieka R
    Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
    Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
    Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
    Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date.
    Yan M; Wang H; Wei R; Li W
    Arch Pharm Res; 2024 Mar; 47(3):249-271. PubMed ID: 38147202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.